| human | Q5 |
| P496 | ORCID iD | 0000-0002-0446-9039 |
| P735 | given name | Stefan | Q4927128 |
| Stefan | Q4927128 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q33590458 | (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor |
| Q87204655 | A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities |
| Q51697298 | A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial. |
| Q92626424 | AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel |
| Q59393973 | Abstract 4433: Deregulated microRNAs in NF1 derived malignant peripheral nerve sheath tumors (MPNST) and their role in carcinogenesis |
| Q64989078 | Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review. |
| Q98185916 | Active surveillance in desmoid-type fibromatosis: A systematic literature review |
| Q54471115 | Allele-specific, non-extendable primer blocker PCR (AS-NEPB-PCR) for DNA mutation detection in cancer. |
| Q38383865 | Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial |
| Q35927942 | An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients |
| Q53706885 | An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells. |
| Q57185095 | An optimized workflow to evaluate estrogen receptor gene mutations in small amounts of cell-free DNA |
| Q39673956 | Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. |
| Q91563829 | Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer |
| Q33382956 | Angiogenesis inhibition in non-GIST soft tissue sarcomas |
| Q37090760 | Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. |
| Q40441542 | Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions. |
| Q37215307 | Application of prolonged microdialysis sampling in carboplatin-treated cancer patients |
| Q55068565 | Are immune signatures a worthwhile tool for decision making in early-stage human epidermal growth factor receptor 2-positive breast cancer? |
| Q98288364 | Assessing the Desmoid-Type Fibromatosis Patients' Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries |
| Q88475917 | Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients |
| Q33365881 | Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response |
| Q92110595 | Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials |
| Q90202507 | Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer |
| Q33908105 | Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction |
| Q33516415 | Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry |
| Q81538332 | Bleomycin and scuba diving: where is the harm? |
| Q96125195 | Bridging the Translational Divide in Oncology: In Vivo Testing of Chemo-Sensitivity |
| Q34112732 | CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes |
| Q33226457 | Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer? |
| Q33777407 | Cancer clinical trials--do we need a new algorithm in the age of stratified medicine? |
| Q39985765 | Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen |
| Q33270316 | Cells meeting our immunophenotypic criteria of endothelial cells are large platelets |
| Q37615789 | Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study |
| Q49937482 | Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer |
| Q43269985 | Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer |
| Q92753431 | Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel |
| Q53073587 | Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. |
| Q42847647 | Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation. |
| Q48029978 | Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia? |
| Q38301465 | Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? |
| Q84900778 | Circulating tumor cell isolation and diagnostics: toward routine clinical use |
| Q37467531 | Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer |
| Q47433561 | Circulating tumor cells and sample size: the more, the better. |
| Q49025873 | Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer |
| Q52714347 | Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. |
| Q33304738 | Circulating tumour cell detection on its way to routine diagnostic implementation? |
| Q34150982 | Clinical value of circulating endothelial cell detection in oncology. |
| Q100723889 | Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA |
| Q49495707 | Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out. |
| Q93574475 | Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients |
| Q33374543 | Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage. |
| Q33958257 | Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes |
| Q38211564 | Current clinical trials for advanced osteosarcoma and soft tissue sarcoma |
| Q33340493 | Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis |
| Q99572646 | Defining the dimensions of Circulating Tumor Cells in a large series of breast, prostate, colon, and bladder cancer patients |
| Q38094855 | Denosumab in breast cancer treatment |
| Q89791190 | Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors |
| Q34669926 | Designing transformative clinical trials in the cancer genome era. |
| Q33551239 | Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. |
| Q51011741 | Development and validation of an UPLC-MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair. |
| Q38297766 | Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature |
| Q33861964 | Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients |
| Q99708462 | Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics |
| Q102068357 | Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors |
| Q80848994 | Dose selection in phase I studies: why we should always go for the top |
| Q46482167 | Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer |
| Q37072355 | Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment |
| Q28068291 | ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients |
| Q81367871 | Editorial: the long and winding road to better cancer cell-specific therapies |
| Q33712655 | Effects of Mannose-Binding Lectin Polymorphisms on Irinotecan-Induced Febrile Neutropenia |
| Q53419829 | Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. |
| Q47127824 | Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients |
| Q55021818 | Evidence on the cost of breast cancer drugs is required for rational decision making. |
| Q38694793 | Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. |
| Q58282445 | External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study |
| Q50630417 | First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy. |
| Q33348120 | GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design |
| Q37576155 | Gastrointestinal stromal tumors II: medical oncology and tumor response assessment |
| Q54169673 | Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. |
| Q33283678 | Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo |
| Q91322927 | Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors |
| Q47623328 | Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. |
| Q33296147 | Gynaecological sarcomas |
| Q89401504 | Health policy: Affordability of drugs used in oncology health care |
| Q92004623 | High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane |
| Q61814374 | High-throughput isolation of circulating tumor DNA: a comparison of automated platforms |
| Q44850155 | Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen |
| Q30739776 | How to decide whether to offer and use "nonstandard" therapies in patients with advanced sarcomas and gastrointestinal stromal tumors: global variations in clinical practice, assessment, and access to therapies in diseases with limited incidence and |
| Q90266423 | Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study |
| Q38375877 | Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial |
| Q54281890 | Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors. |
| Q33708774 | Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells |
| Q58110348 | Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients |
| Q91593867 | Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials |
| Q89866374 | Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples |
| Q86436313 | Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy |
| Q53248796 | Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report. |
| Q33289378 | Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment |
| Q92564457 | Incorporating liquid biopsies into treatment decision-making: obstacles and possibilities |
| Q34852414 | Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study |
| Q34317938 | Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study |
| Q80531511 | Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated |
| Q81304115 | Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects |
| Q38167919 | International expert opinion on patient-tailored management of soft tissue sarcomas |
| Q33738688 | International study on inter-reader variability for circulating tumor cells in breast cancer |
| Q46960024 | Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature |
| Q33513005 | It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies |
| Q34509268 | KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue |
| Q89721442 | Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review |
| Q34579008 | Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells |
| Q87859335 | Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy |
| Q40490789 | Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy |
| Q38860387 | Lysosomal Sequestration Determines Intracellular Imatinib Levels |
| Q40933473 | Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. |
| Q33385878 | Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. |
| Q82316347 | Medical oncology: clinical value of circulating tumor cells in breast cancer |
| Q92875099 | MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma |
| Q45854086 | MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. |
| Q35187892 | MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microRNA mediated regulation of HIF3α |
| Q84274804 | MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer |
| Q91321329 | Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study |
| Q41260173 | Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis |
| Q60907386 | Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers |
| Q93018182 | Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs |
| Q37644818 | Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer |
| Q83126160 | Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR |
| Q26830525 | Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design |
| Q33389572 | Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res |
| Q92729617 | Natural history of well-differentiated liposarcoma of the extremity compared to patients treated with surgery |
| Q50913835 | Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. |
| Q33379228 | Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status |
| Q37366859 | Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy |
| Q99709293 | Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors |
| Q79748422 | Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib |
| Q93002945 | Novel methods to diagnose leptomeningeal metastases in breast cancer |
| Q33490151 | On the origin of (CD105+) circulating endothelial cells |
| Q90911765 | Pan-cancer whole-genome analyses of metastatic solid tumours |
| Q45267349 | Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. |
| Q41864217 | Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience |
| Q33447149 | Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu |
| Q28287163 | Pazopanib, a new therapy for metastatic soft tissue sarcoma |
| Q33420218 | Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area |
| Q33210230 | Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients |
| Q46942266 | Potential biomarkers in metastatic gastrointestinal stromal tumors. |
| Q33263451 | Practical aspects of managing gastrointestinal stromal tumors. |
| Q47592150 | Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. |
| Q88009530 | Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database |
| Q92091033 | Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer |
| Q37352090 | Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor |
| Q57571056 | Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas |
| Q52701991 | Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sa |
| Q37650706 | Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure |
| Q83854694 | Quantification of circulating endothelial cells by flow cytometry |
| Q92217540 | RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer |
| Q84813404 | Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib |
| Q64947136 | Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material. |
| Q28303717 | Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance |
| Q30959559 | Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response |
| Q64275408 | Self-Seeding Microwells to Isolate and Assess the Viability of Single Circulating Tumor Cells |
| Q48534891 | Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatment |
| Q28286274 | Side effects of interferon-alpha therapy |
| Q42257098 | Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA. |
| Q40431521 | Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases |
| Q57816403 | Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress |
| Q51017184 | Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. |
| Q36173335 | Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? |
| Q91687113 | Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients |
| Q39828587 | T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients |
| Q33530527 | T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies |
| Q42552126 | T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness |
| Q21131200 | TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu |
| Q91410030 | TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer |
| Q54122869 | Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. |
| Q38982558 | Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia |
| Q50447674 | Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointesti |
| Q33208578 | Thalidomide in solid tumours: the resurrection of an old drug |
| Q84737614 | The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients |
| Q38842194 | The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature |
| Q53686719 | The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. |
| Q91716821 | The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis of Individual Patient Data |
| Q42930809 | The addition of pravastatin to chemotherapy in advanced gastric carcinoma: A randomised phase II trial |
| Q53135356 | The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. |
| Q45764917 | The future of drug development? Seeking evidence of activity of novel drugs in small groups of patients |
| Q90391403 | The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies |
| Q91361895 | The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact |
| Q43611802 | The impact of age on outcome of embryonal and alveolar rhabdomyosarcoma patients. A multicenter study |
| Q33308460 | The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas |
| Q33212368 | The potential of statins as part of anti-cancer treatment |
| Q92612599 | The role of mitochondrial DNA in breast tumors |
| Q37267842 | The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? |
| Q38815604 | The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer |
| Q84353342 | The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system |
| Q34592273 | Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity |
| Q83222464 | Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience |
| Q34469701 | Tumor volume as an alternative response measurement for imatinib treated GIST patients |
| Q38882097 | Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered |
| Q33228022 | Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care |
| Q54533556 | Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. |
| Q92236177 | Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis |
| Q90350143 | Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations |
| Q95564126 | [Drug research in oncology; advances in the genome era] |
| Q54377128 | mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. |
| Q41136311 | mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. |
| Q33621431 | mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells |
Search more.